Elanco

Companion Animal Specialty Drugs Market 2020-2024: COVID-19 Business Continuity Plan | Evolving Opportunities with Bayer AG and Boehringer Ingelheim International GmbH | Technavio

Retrieved on: 
Tuesday, September 8, 2020
Health, Consumer, Infectious diseases, Pets, Pharmaceutical, Biotechnology, Veterinary, Life sciences, Articles, Industries, Elanco, Bayer, Specialty drugs in the United States, Pharmaceutical industry in China

The global companion animal specialty drugs market is expected to grow by USD 2.29 billion as per Technavio.

Key Points: 
  • The global companion animal specialty drugs market is expected to grow by USD 2.29 billion as per Technavio.
  • In addition, enhanced product offerings are anticipated to boost the growth of the companion animal specialty drugs market.
  • Major Five Companion Animal Specialty Drugs Companies:
    Bayer AG operates its business through segments such as Pharmaceuticals, Crop science, and Consumer health.
  • Elanco Animal Health Inc. operates its business through segments such as Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein and Health, and Food Animal Ruminants and Swine.

Elanco Announces Acquisition of Prevtec Microbia Swine Vaccine Company

Retrieved on: 
Thursday, August 1, 2019
Agriculture, Natural Resources, Health, Veterinary, Life sciences, Articles, Eli Lilly and Company, Biotechnology, Vaccine, Antibiotic, Elanco, Prevtec Microbia

Elanco Animal Health Incorporated (NYSE: ELAN) today announced the acquisition of Montreal-based Prevtec Microbia Inc. (Prevtec), a biotechnology startup specializing in the development of vaccines that help prevent bacterial diseases in food animals.

Key Points: 
  • Elanco Animal Health Incorporated (NYSE: ELAN) today announced the acquisition of Montreal-based Prevtec Microbia Inc. (Prevtec), a biotechnology startup specializing in the development of vaccines that help prevent bacterial diseases in food animals.
  • By acquiring Prevtec and bringing the Coliprotec line into Elancos swine portfolio, Elanco will look to expand registration to other key geographies.
  • In the past year, Elanco has taken a number of strategic steps to advance the company for greater success in the swine industry.
  • Prevtec Microbia is a Canadian biotechnology company developing and commercializing sustainable solutions as alternatives to antibiotics to improve animal health, production performance and food safety.

Elanco Announces R&D Collaboration with AgBiome for Swine Nutritional Health Innovation

Retrieved on: 
Thursday, June 27, 2019
Biotechnology, Retail, Health, Other Science, Research, Agriculture, Natural Resources, Science, Veterinary, Food, Beverage, Articles, Bacteriology, Digestive system, Probiotic, Eli Lilly and Company, Innovation, Medical specialties, Life sciences, Elanco, AgBiome, Inc.

Elanco Animal Health Incorporated (NYSE: ELAN), announced today a new global R&D collaboration with AgBiome, Inc. to develop nutritional health products for swine.

Key Points: 
  • Elanco Animal Health Incorporated (NYSE: ELAN), announced today a new global R&D collaboration with AgBiome, Inc. to develop nutritional health products for swine.
  • The research and development collaboration with AgBiome is intended to deliver innovative probiotic solutions to some of swine producers greatest gut health challenges.
  • Elanco will combine AgBiomes success in crop science with its expertise in animal health to bring innovative new solutions.
  • This agreement furthers Elancos targeted, value-generating IPP strategy (Innovation, Portfolio and Productivity), bringing a consistent, sustainable flow of innovation in the fast growing nutritional health market.